{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:22:19Z","timestamp":1783786939884,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ygyno.2017.05.013","type":"journal-article","created":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T11:00:21Z","timestamp":1495191621000},"page":"279-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial"],"prefix":"10.1016","volume":"146","author":[{"given":"C.","family":"Dinkic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Eichbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Grischke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wallwiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Marme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.05.013_bb0005","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2017.05.013_bb0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1008303300675","article-title":"The Gynecologic Oncology Group experience in ovarian cancer","volume":"10","author":"McGuire","year":"1999","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0015","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2017.05.013_bb0020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.03.004","article-title":"Ovarian cancer","volume":"60","author":"Colombo","year":"2006","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0025","first-page":"427","article-title":"Antiangiogenic scheduling of lower dose cancer chemotherapy","volume":"7","author":"Gately","year":"2001","journal-title":"Cancer J."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0030","first-page":"2731","article-title":"Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water","volume":"62","author":"Man","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0035","doi-asserted-by":"crossref","first-page":"12917","DOI":"10.1073\/pnas.2135406100","article-title":"Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy","volume":"100","author":"Bocci","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/mdf013","article-title":"Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1471-2407-7-65","article-title":"Cyclophosphamide \u201cmetronomic\u201d chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer","volume":"7","author":"Samaritani","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2017.05.013_bb0050","first-page":"7501","article-title":"Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo","volume":"61","author":"Bello","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0055","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0060","first-page":"221","article-title":"Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts","volume":"8","author":"Klement","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0065","first-page":"7846","article-title":"Antiangiogenic therapy of established tumors in human skin\/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide","volume":"61","author":"Takahashi","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0070","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ygyno.2007.07.017","article-title":"Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer","volume":"107","author":"Chura","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0080","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12094-008-0254-7","article-title":"Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer","volume":"10","author":"Jurado","year":"2008","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0085","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0090","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","article-title":"Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 620)","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0095","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","article-title":"Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis","volume":"56","author":"Koll\u00e1r","year":"2017","journal-title":"Acta Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0100","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1200\/JCO.2009.23.9749","article-title":"Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I\/II resectable non-small-cell lung cancer","volume":"28","author":"Altorki","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0110","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0115","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ygyno.2016.10.021","article-title":"Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy","volume":"143","author":"Lee","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0120","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0125","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/bjd.14727","article-title":"An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel","volume":"175","author":"Thurneysen","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00280-012-1982-z","article-title":"A phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors","volume":"71","author":"Plummer","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0140","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0145","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0150","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer","volume":"18","author":"Gordon","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0155","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/jjco\/hyn101","article-title":"Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chem","volume":"38","author":"Katsumata","year":"2008","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0160","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","article-title":"Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel","volume":"63","author":"Shapiro","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0165","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1023\/A:1008469212268","article-title":"A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer","volume":"9","author":"Friedlander","year":"1998","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0170","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/annonc\/mdm136","article-title":"Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study","volume":"18","author":"Ferrandina","year":"2007","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0175","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.05.013_bb0180","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2017.05.013_bb0185","author":"Duska"},{"key":"10.1016\/j.ygyno.2017.05.013_bb0190","author":"Richardson"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T17:56:17Z","timestamp":1535824577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817308521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0090825817308521"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.05.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}